Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Improvement in results on a noninvasive urinary biomarker panel at 3 months among patients with lupus nephritis predicted a clinical response at 1 year. A noninvasive urinary biomarker panel predicts ...

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are confirmed in larger studies, research presented here suggested. Measurement of 12 ...

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing ...

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care ...

WASHINGTON — An investigational 12-protein panel of urinary biomarkers predicted histologically active lupus nephritis (LN) with 86% accuracy, according to research presented at the American College ...

A Roche drug that is one of the company’s top cancer products is expanding to autoimmune disease with a new FDA approval in lupus nephritis. The intravenously infused drug, Gazyva, may now be used to ...

The FDA approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. Obinutuzumab’s safety profile ...

Circulating microRNAs as well as urinary extracellular vesicles plus cytokines potentially reflect lupus nephritis activity beyond traditional laboratory parameters. Circulating microRNAs (miRNAs) and ...

Roche Holding said the Food and Drug Administration approved a drug for the treatment of adults with lupus nephritis, a potentially life-threatening autoimmune disease that commonly affects the ...